


## Ovarian stimulation and endometrial receptivity: the body of evidence

Nick Macklon

Professor of Obstetrics and Gynaecology, University of Copenhagen (Roskilde) and University of Southampton, UK.




## Implantation is rate limiting step in IVF



CDC


## Optimal number of oocytes after long protocol?

Live birth rate and oocyte yield



Van der Gaast et al, RBM Online, 2006

## The Iceberg of pregnancy loss





# Ovarian stimulation damages the endometrium

Natural cycle,  
day of ovulation

When advanced >3 days  
**NO IMPLANTATION**  
Kolibianakis, *et al.*  
*Fertil Steril*, 2002.


Stimulated cycle, day of OPU  
Secretory features present:  
Subnuclear vacuoles  
displacing nucleus



Devroey, *et al.* TEM. 2004;15:84.

## Controlled Ovarian Stimulation Induces a Functional Genomic Delay of the Endometrium with Potential Clinical Implications

José A. Horcajadas, Pablo Minguez, Joaquín Dopazo, Francisco J. Esteban, Francisco Dominguez, Linda C. Giudice, Antonio Pellicer, and Carlos Simón



25 natural cycles

25 stimulated cycles

Biopsies on day

1

3

5

7



after LH rise/hCG

*J Clin Endocrinol Metab.* 93:4500-4510, 2008.

# Uterine secretomics: a window on the maternal-embryo interface

Ying Cheong, M.D.,<sup>a</sup> Carolien Boomsma, Ph.D.,<sup>b</sup> Cobi Heijnen, Ph.D.,<sup>b,c</sup> and Nick Macklon, Ph.D.<sup>a</sup>

<sup>a</sup> Princess Anne Hospital, University of Southampton, Southampton, United Kingdom; <sup>b</sup> University Medical Centre Utrecht, Utrecht, the Netherlands; and <sup>c</sup> M.D. Anderson Cancer Center, University of Texas, Houston, Texas




Non-invasive  
Simple  
Does not disrupt implantation


## Ovarian stimulation on intra-uterine cytokine profile

UNIVERSITY OF  
**Southampton**  
School of Medicine

### Pro-inflammatory cytokines



### Anti-inflammatory cytokines



### Pro-and anti-inflammatory properties

Multivariable analysis in 203 patients showed significant relations between the number of oocytes retrieved and secretion concentrations of IL-12, Dkk-1 (positive) and VEGF, IL-15 (negative).




## IVF and the Endometrium

Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation

Wen-ge Ma<sup>1</sup>, Haengseok Song<sup>1</sup>, Sanjoy K. Das, Bibhash C. Paria, and Sudhansu K. Dey<sup>1</sup>

A scheme depicting modulation of the window of receptivity in the P4-primed uterus in response to changing estrogen levels. This scheme shows that estrogen at low threshold level extends the window of uterine receptivity for implantation, but higher levels rapidly close this window, transforming the uterus into a refractory state.




## Impact of high E2 on P action

- Premature reduction in PR receptors  
(Hadi, *et al. Hum Reprod.* 2004.)
- Reduced PR and ER expression  
(Devroey, *et al. TEM.* 2004.)
- Supraphysiological E2 may increase sensitivity to P action,  
and thus secretory advancement.  
(Jacobs, *et al. JCEM.* 1987.)
- Accentuated proliferative and early secretory changes  
before hCG, in absence of rise in Progesterone.  
(Marchini, *et al. Fertil Steril.* 1994)


Macklon, *et al. Endocrine Reviews.* 2006.

## What about clomiphene?


## Clomiphene reduces Integrin $\beta_3$ and disrupts PR downregulation



Control



CC treated



PR expression

Palomino, et al. Fertil Steril. 2005;83:587.

## What about impact of high Progesterone levels?

## Relationship between serum P levels on the day of hCG and ongoing pregnancy rate

- A retrospective, observational, single-centre cohort study

Progesterone levels	Pregnancy rate
< or = 1.5 ng/ml	31%
>1.5 ng/ml	19%
<b>P &lt; 0.001</b>	

- Multivariate regression analysis showed that **daily FSH** dose, **number of oocytes** and **estradiol values** on the day of hCG administration were positively associated with progesterone levels (P < 0.0001 for all).

Bosch E. *Hum Reprod.* 2010;25:2092–2100.

Hum. Reprod. Advance Access published March 14, 2012  
Human Reproduction, Vol.0, No.0 pp. 1–7, 2012  
doi:10.1093/humrep/des066

human reproduction ORIGINAL ARTICLE *Reproductive endocrinology*

### GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study<sup>†</sup>

E.G. Papanikolaou<sup>1,2,3,\*</sup>, G. Pados<sup>1,3</sup>, G. Grimbizis<sup>1,3</sup>, E. Bili<sup>1,3</sup>, L. Kyriazi<sup>3</sup>, N.P. Polyzos<sup>4</sup>, P. Humaidan<sup>5</sup>, H. Tournaye<sup>4</sup>, and B. Tarlatzis<sup>1,3</sup>

190 patients

When progesterone exceeded the threshold of 1.5 ng/ml, lower delivery rates:

<b>Agonist group</b>	9.5 versus 31.8%	P= 0.03
<b>Antagonist</b>	14.3 versus 34.3%	P= 0.07

P rise >1.5 ng/ml in 24% of the antagonist group and 23% agonist group

**“9 out of 10 patients failed to achieve a clinical pregnancy whenever progesterone levels exceeded the threshold of 1.5 ng/ml”**




**Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression**

I Van Vaerenbergh <sup>a,\*</sup>, HM Fatemi <sup>b</sup>, C Blockeel <sup>b</sup>, L Van Lommel <sup>c</sup>, P In't Veld <sup>a</sup>, F Schuit <sup>c</sup>, EM Kolibianakis <sup>d</sup>, P Devroey <sup>b</sup>, C Bourgain <sup>a</sup>

Patient's progesterone concentration (ng/ml)	Clinical outcome	Histological dating <sup>a</sup>
<b>Group A (progesterone ≤0.9 ng/ml)</b>		
0.68	Pregnant	+2 days
0.69	Not pregnant	+2 days
0.9	Pregnant	+2 days
<b>Group B (progesterone 1–1.5 ng/ml)</b>		
1.2	Not pregnant	+2 days
1.1	Not pregnant	+2 days
1.44	Pregnant	+3 days
1.1	Pregnant	+3 days
1.05	Not pregnant	+2 days
1.3	Not pregnant	+4 days
<b>Group C (progesterone &gt;1.5 ng/ml)</b>		
1.61	Not pregnant	+4 days
1.8	Not pregnant	+4 days
1.54	Not pregnant	+2 days
1.93	Not pregnant	Late proliferative
1.7	Biochemical pregnancy	+3 days

**Advancement of gene expression**



Differential gene expression between groups of progesterone concentration (A = ≤0.9 ng/ml; B = 1–1.5 ng/ml; C = >1.5 ng/ml)

<sup>a</sup>(Advanced) endometrial maturation as compared with the chronological cycle day.

Reproductive BioMedicine Online (2011) 22, 263–271.

**Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis**

E. Labarta<sup>1,\*</sup>, J.A. Martínez-Conejero<sup>2</sup>, P. Alamá<sup>1</sup>, J.A. Horcajadas<sup>2</sup>, A. Pellicer<sup>1</sup>, C. Simón<sup>1,2</sup>, and E. Bosch<sup>1</sup>

<sup>1</sup>Department of Human Reproduction, Instituto Valenciano de Infertilidad, University of Valencia, Plaza de la Piedad Local 3, 46105 Valencia, Spain <sup>2</sup>Genoma, Valencia, Spain

12 oocyte donors

Progesterone level (On day of hCG)	# donors	# genes significantly dysregulated	# gene targets* over-regulated
>1.5 ng/ml (study group)	6	140	13
<1.5 ng/ml (control group)	6		

\*Of the 25 gene targets previously proposed as markers for endometrial receptivity

- Endometrial samples collected 7 days after the hCG injection
- Endometria compared with the control endometria, regardless of the GnRH analogue employed

# Beyond Implantation


## The endometrium and the baby

- Perinatal outcome of singleton siblings born after Assisted Reproductive Technology and spontaneous conception

Danish National Sibling-Cohort study

**AIM:** Separate the effects of the maternal characteristics and the effects of infertility


### Birthweight (g), adjusted\*



\*maternal age, parity, year of birth, sex

### IVF procedure or Ovarian Stimulation?

### Cryo: Birthweight (g), adj.\*



\*maternal age, parity, year of birth, sex

## Freeze all frees all!

UNIVERSITY OF  
**Southampton**  
School of Medicine




- Doctor free to stimulate ovaries without disrupting endometrium
- Women free of OHSS risk
- Embryos free to implant in more physiological environment
- Babies free of impact of ovarian stimulation on development

## **‘E-FREEZE’**

### **UK Multicentre RCT**


- Elective freeze all versus fresh transfer n=918
- Powered for livebirth rate
- Costs, health outcomes etc
- Starts December 2015




## What can we do to ameliorate the impact of ovarian stimulation on the endometrium?

25

### Does reducing E2 exposure improve implantation rates?



1. Significant decreases in implantation and pregnancy rates when E2 levels >2500 pg/ml on day of hCG<sup>1</sup>
2. Stepdown protocol improves outcomes in high responders<sup>2</sup>



Reproductive outcome of the step-down cycle versus the previous failed cycle of IVF.

Variable	Previous cycle (n = 24)	Step-down cycle (n = 24)	P value
Patient age (y)	31.1 ± 1.4	31.6 ± 1.2	NS
GnRH analogue (d)	20.2 ± 0.6	22.9 ± 0.7	NS
Days of treatment	9.7 ± 0.4	10.6 ± 0.1	NS
Ampules of gonadotropins	27.2 ± 2.1	22.4 ± 0.8	NS
E <sub>2</sub> level (pg/mL)	5,770 ± 650	1,919 ± 477	.001
No. of oocytes	24.0 ± 1.9	18.1 ± 2.1	.001
Fertilization rate (%)	71.2	74.2	NS
No. of embryos transferred	3.8 ± 0.2	3.3 ± 0.2	NS
No. of embryos frozen	6.2 ± 1.0	2.3 ± 0.7	.002
Pregnancy rate (%)	0	64.2	.0001
Implantation rate (%)	0	29.3	.0001

Note: Values are expressed as means ± SE unless otherwise indicated. NS = not significant.

1. Simon, *et al. Hum Reprod.*1995;10:2432.
2. Simon, *et al. Fertil Steril.*1998;70:234.

Does milder stimulation reduce estradiol and progesterone levels at the end of the follicular phase?

**Follicular Phase Endocrine Characteristics during Ovarian Stimulation and GnRH Antagonist Cotreatment for IVF: RCT Comparing recFSH Initiated on Cycle Day 2 or 5**

Christophe Blockeel,\* Monique D. Sterrenburg,\* Frank J. Broekmans, Marinus J. C. Eijkemans, Johan Smitz, Paul Devroey, and Bart C. J. M. Fauser

Centre for Reproductive Medicine (C.B., J.S., P.D.), Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium; Department of Reproductive Medicine and Gynecology (M.D.S., F.J.B., M.J.C.E., B.C.J.M.F.) and Julius Centre for Health Sciences and Primary Care (M.J.C.E.), University Medical Centre Utrecht, 3508 GA Utrecht, The Netherlands

Blockeel C, et al. *JCEM*. 2011;96:1122-1128.


**Follicular Phase Endocrine Characteristics during Ovarian Stimulation and GnRH Antagonist Cotreatment for IVF: RCT Comparing recFSH Initiated on Cycle Day 2 or 5**

Christophe Blockeel,\* Monique D. Sterrenburg,\* Frank J. Broekmans, Marinus J. C. Eijkemans, Johan Smitz, Paul Devroey, and Bart C. J. M. Fauser

Follicular characteristics and cycle outcome measures

	CD2 group (n = 33)	CD 5 group (n = 39)	P
Total dose of recFSH (IU)	1364 ± 226	1177 ± 295	<0.01
recFSH duration (days)	9.1 ± 1.5	7.8 ± 2.0	<0.01
Duration follicular phase (days)	10.1 ± 1.5	11.9 ± 2.0	<0.01

Blockeel C, et al. *JCEM*. 2011;96:1122-1128.



Is there a role for adjuvant medication to reduce supraphysiological E and P action?

## Aromatase inhibitors?

- Reduce E<sub>2</sub> levels at end of follicular phase.
- Used in IVF to reduce E<sub>2</sub> exposure for Breast Cancer patients.
- Published data available in poor responders and cancer patients.
- No evidence of increased risk fetal anomalies (Tulandi, *et al.*)
- 'RIOT' study commenced in Copenhagen

## Progesterone Antagonists?



### Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis

Richard J. Paulson, M.D.\*†  
Mark V. Sauer, M.D.†‡  
Rogelio A. Lobo, M.D.†‡

*Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, California*

**Objective:** To manipulate the luteal endometrial progression by the use of antiprogestins.

**Design:** Prospective controlled clinical trial.

**Setting:** The IVF program of the University of Southern California School of Medicine, Los Angeles, California.

**Patient(s):** Thirteen oocyte donors and 20 oocyte recipients.

**Intervention(s):** Controlled ovarian hyperstimulation of oocyte donors, administration of two doses of 2.5 mg of RU486 to the study group, and endometrial biopsies.

**Main Outcome Measure(s):** Serum E<sub>2</sub> and P levels, histologic dating of the endometrium, endometrial ultrastructure by scanning electron microscopy.

**Result(s):** No difference in serum E<sub>2</sub> or P levels was noted after RU486 administration. The histologic dating was advanced in oocyte donors as compared with recipients undergoing artificial cycles but returned to normal (in phase) after RU486. Pinopods were noted in all recipient biopsies and in donors treated with RU486 but in only one of four biopsies in donor controls.

**Conclusion(s):** Cycles with controlled ovarian hyperstimulation are associated with high early luteal P levels and advanced endometrial histology. Low doses of RU486 may correct the precocious luteinization and restore endometrial receptivity. Fertil Steril® 1997;67:321-5

## Conclusions

- Despite embryo selection, implantation rates after IVF are lower than after spontaneous conceptions
- Ovarian stimulation disrupts the endometrium and intra-uterine environment
- Clomiphene, supraphysiological estradiol and progesterone all implicated
- Freeze all strategies await assessment
- Endocrine modulation strategies being explored.

# Acknowledgements

Alex Kermack  
Keith Godfrey  
Philip Calder  
Franchesca Houghton  
Tom Fleming  
  
Gijs Teklenburg  
Carolien Boomsma  
Lotte Weimar  
Frank Holstege  
Cobi Heijnen  
Bart Fauser  
  
Birgit Gellersen  
Jan Brosens  
  
Xiao Shilong  
Hywel Morgan  
Ying Cheong  
  
Morten Petersen  
Soeren Ziebe  
Sven Skouby  
Thomas Hvidt

UNIVERSITY OF  
**Southampton**  
School of Medicine

**NHS**  
National Institute for  
Health Research

